Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Moleculin Biotech is a biotechnology business based in the US. Moleculin Biotech shares (MBRX) are listed on the NASDAQ and all prices are listed in US Dollars. Moleculin Biotech employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $1.26 |
|---|---|
| 52-week range | $0.82 - $2.05 |
| 50-day moving average | $1.23 |
| 200-day moving average | $1.38 |
| Wall St. target price | $8.67 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.64 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.26 from 2023-01-25
| 1 week (2023-01-20) | -1.56% |
|---|---|
| 1 month (2022-12-27) | 13.51% |
| 3 months (2022-10-27) | 35.15% |
| 6 months (2022-07-27) | -25.44% |
| 1 year (2022-01-23) | N/A |
|---|---|
| 2 years (2021-01-27) | 29.19% |
| 3 years (2020-01-27) | 39.66% |
| 5 years (2018-01-26) | 1.97 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -23.36% |
| Return on equity TTM | -35.91% |
| Profit margin | 0% |
| Book value | $2.04 |
| Market capitalisation | $36.9 million |
TTM: trailing 12 months
We're not expecting Moleculin Biotech to pay a dividend over the next 12 months.
Moleculin Biotech's shares were split on a 1:6 basis on 31 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Moleculin Biotech shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Moleculin Biotech shares which in turn could have impacted Moleculin Biotech's share price.
Over the last 12 months, Moleculin Biotech's shares have ranged in value from as little as $0.817 up to $2.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moleculin Biotech's is 1.9627. This would suggest that Moleculin Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Moleculin Biotech, Inc. , a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z. o.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
